Macrogenics (MGNX) Net Cash Flow (2012 - 2026)
Macrogenics (MGNX) posted quarterly Net Cash Flow of $9.3 million for Q1 2026, up 124.95% year-over-year from $4.1 million in Q1 2025, and up 140.59% quarter-over-quarter from -$22.9 million in Q4 2025.
Macrogenics (MGNX) Net Cash Flow (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Net Cash Flow for 15 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 124.95% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at -$79.1 million (down 221.22% YoY), while the FY2025 annual figure was -$125.6 million, down 253.42% from the prior year.
- Net Cash Flow rose to $9.3 million in Q1 2026 per MGNX's latest filing, from -$22.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $115.4 million in Q1 2023 and bottomed at -$115.5 million in Q2 2023.
- Historically, Net Cash Flow has averaged -$3.4 million across 5 years, with a median of -$14.9 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 3905.38% — and 2025, when it slumped 812.66%.
- Macrogenics' Net Cash Flow stood at $24.9 million in 2022, then sank by 55.57% to $11.1 million in 2023, then plunged by 70.93% to $3.2 million in 2024, then plunged by 812.66% to -$22.9 million in 2025, then surged by 140.59% to $9.3 million in 2026.
- Business Quant data shows MGNX's Net Cash Flow at $9.3 million in Q1 2026, -$22.9 million in Q4 2025, and -$50.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 9.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.30 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | -22.91 Mn |
| Dec 31, 2025 | -22.91 Mn |
| Sep 30, 2025 | -50.56 Mn |
| Sep 30, 2025 | -50.56 Mn |
| Jun 30, 2025 | -14.88 Mn |
| Jun 30, 2025 | -14.88 Mn |
| Mar 31, 2025 | -37.27 Mn |
| Mar 31, 2025 | -37.27 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 95.69 Mn |
| Sep 30, 2024 | 95.69 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Mar 31, 2024 | -20.60 Mn |
| Mar 31, 2024 | -20.60 Mn |
| Dec 31, 2023 | 11.06 Mn |
| Dec 31, 2023 | 11.06 Mn |